title: Treatment of non-small cell lung cancer (NSCLC).
abstract: Radical surgery is the standard of care for fit stage I non-small cell lung cancer (NSCLC) patients. Adjuvant treatment should be offered only as part of an investigation trial. Stage II and IIIA adjuvant cisplatin-based chemotherapy remains the gold standard for completely resected NSCLC tumors. Additionally radiotherapy should be offered in patients with N2 lymph nodes. In advanced stage IIIB/IV or inoperable NSCLC pts, a multidisciplinary treatment should be offered consisted of 4 cycles of cisplatin-based chemotherapy plus a 3(rd) generation cytotoxic agent or a cytostatic (anti-EGFR, anti-VEGFR) drug.
authors.affiliation: Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Zarogoulidis
authors.forename: Paul
authors.initials: P
authors.lastname: Zarogoulidis
authors.forename: Kaid
authors.initials: K
authors.lastname: Darwiche
authors.forename: Efimia
authors.initials: E
authors.lastname: Boutsikou
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Machairiotis
authors.forename: Kosmas
authors.initials: K
authors.lastname: Tsakiridis
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Katsikogiannis
authors.forename: Ioanna
authors.initials: I
authors.lastname: Kougioumtzi
authors.forename: Ilias
authors.initials: I
authors.lastname: Karapantzos
authors.forename: Haidong
authors.initials: H
authors.lastname: Huang
authors.forename: Dionysios
authors.initials: D
authors.lastname: Spyratos
keywords: Non-small cell lung cancer (NSCLC); lung cancer; targeted treatment; treatment